AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22849962 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 71
Study 22849962 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 71
Study 20627618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash reimbursement after each study visit (maximum possible = $425 over 12 weeks)
Number of subjects: 70
Study 18638006 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 30
Study 18638006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day plus tadalafil 20 mg/day
Number of subjects: 30
Study 15988786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensionless vaginal tape (TVT)
Number of subjects: 182
Study 15988786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal slingplasty (IVS)
Number of subjects: 182
Study 15988786 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic arc procedure (SPARC)
Number of subjects: 182
Study 15988786 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 182
Study 11211570 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic practices for the first five months of the course
Number of subjects: 54
Study 11211570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yogic exercises during the first five months)
Number of subjects: 54
Study 9662676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 235
Study 9662676 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise program
Number of subjects: 235
Study 7838778 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0
Study 7838778 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized observational studies
Number of subjects: 0
Study 2900410 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded therapeutic suggestions during general anaesthesia
Number of subjects: 39
Study 2900410 — intervention group
Group type: COMPARATOR
Intervention: Blank tape (control)
Number of subjects: 39
Study 30271132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 43
Study 30271132 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 43
Study 27262892 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy of the involved shoulder for 10 weeks
Number of subjects: 99
Study 27262892 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy of the uninvolved shoulder for 10 weeks (Control group)
Number of subjects: 99
Study 25249453 — intervention group
Group type: EXPERIMENTAL
Intervention: Free glasses provided in class
Number of subjects: 3177
Study 25249453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers for free glasses at a local facility
Number of subjects: 3177
Study 25249453 — intervention group
Group type: COMPARATOR
Intervention: Prescription for glasses only (control group)
Number of subjects: 3177
Study 22386563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined criteria of LMVD and CT
Number of subjects: 94
Study 22386563 — intervention group
Group type: COMPARATOR
Intervention: CT only
Number of subjects: 94
Study 20334449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy for secondary prevention
Number of subjects: 0
Study 20334449 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized antithrombotic therapy
Number of subjects: 0
Study 20334449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 0
Study 20334449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 16963726 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and dietary intervention
Number of subjects: 200
Study 16963726 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement strategies (bilingual staff, culturally adapted materials)
Number of subjects: 200
Study 16131701 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal midsole
Number of subjects: 9
Study 16131701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard midsole
Number of subjects: 9
Study 16131701 — intervention group
Group type: COMPARATOR
Intervention: Soft midsole
Number of subjects: 9
Study 12243609 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin-reuptake inhibitors (SSRIs)
Number of subjects: 200
Study 12243609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 200
Study 12243609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 200
Study 12243609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 200
Study 10030188 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic family nursing intervention
Number of subjects: 198
Study 10030188 — intervention group
Group type: COMPARATOR
Intervention: Regular services (Control)
Number of subjects: 198
Study 8565089 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month short-course chemotherapy
Number of subjects: 287
Study 2614634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore‐Tex periodontal material, held in place by sling sutures of expanded polytetrafluoroethylene (test site)
Number of subjects: 12
Study 2614634 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without Gore‐Tex material (control site)
Number of subjects: 12
Study 775275 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 40
Study 30879358 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 305
Study 30879358 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 305
Study 29785873 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive momentum condition (coming back from 1-7 to 7-7)
Number of subjects: 80
Study 29785873 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative momentum condition (opponent coming back from 7-1 to 7-7)
Number of subjects: 80
Study 29785873 — intervention group
Group type: COMPARATOR
Intervention: Time-out with no specific instructions
Number of subjects: 80
Study 29785873 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-out with task (mastery-approach - MAp) instructions
Number of subjects: 80
Study 29785873 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-out in negative momentum condition
Number of subjects: 80
Study 26850040 — intervention group
Group type: EXPERIMENTAL
Intervention: weight loss via a healthful, guidelines‐based diet and exercise regimen
Number of subjects: 40
Study 26850040 — intervention group
Group type: COMPARATOR
Intervention: wait‐list control
Number of subjects: 40
Study 24194532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT) for 2 weeks
Number of subjects: 80
Study 24194532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT)
Number of subjects: 80
Study 24568070 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Body Image Scale (MBIS) - 46 items
Number of subjects: 671
Study 24568070 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Body Image Scale (MBIS) - 62 items
Number of subjects: 671
Study 20576665 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 70
Study 20576665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17980093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 0.5% moxifloxacin and 0.1% dexamethasone formulation (Vigadexa)
Number of subjects: 139
Study 17980093 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing with 0.5% moxifloxacin (Vigamox) and 0.1% dexamethasone (Maxidex)
Number of subjects: 139
Study 15814546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir prophylaxis
Number of subjects: 205
Study 15814546 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir prophylaxis
Number of subjects: 205
Study 15814546 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 205
Study 15814546 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis or aciclovir alone
Number of subjects: 205
Study 15814546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and cyclosporin-ME
Number of subjects: 205
Study 11943521 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 210
Study 11943521 — intervention group
Group type: COMPARATOR
Intervention: Integrated epidural-general anesthesia
Number of subjects: 210
Study 11943521 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 210
Study 10084367 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training 2 times per week
Number of subjects: 58
Study 10084367 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 58
Study 7595165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge 330 kcal day‐1 diet during the first 12 weeks followed by a well balanced hypocaloric diet (1600 kcal day‐1) with 220 kcal from two sachets of Cambridge diet (group 1)
Number of subjects: 60
Study 7595165 — intervention group
Group type: COMPARATOR
Intervention: Cambridge 330 kcal day‐1 diet during the first 12 weeks followed by the same energy provided by the same principal diet (group 2)
Number of subjects: 60
Study 7595165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 64-week treatment period
Number of subjects: 60
Study 7595165 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD period
Number of subjects: 60
Study 2147859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 25-50 mg/day + ethinyl-estradiol (EE) 20-30 micrograms/day
Number of subjects: 0
Study 2147859 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SPL) 100-200 mg/day
Number of subjects: 0
Study 2147859 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL + bromocriptine (2.5-5 mg/day)
Number of subjects: 0
Study 2147859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) alone or associated with tamoxifen (100 mg + 100 mg/day)
Number of subjects: 0
Study 2147859 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogens in advanced prostatic carcinoma
Number of subjects: 0
Study 2147859 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogens combined with surgical or medical castration (LH-RH analogues)
Number of subjects: 0
Study 458893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (200 ml/m2/d)
Number of subjects: 20
Study 458893 — intervention group
Group type: COMPARATOR
Intervention: Plasma protein derivative (Plasmanate)
Number of subjects: 20
Study 458893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma
Number of subjects: 20
Study 31454713 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation (PDI) applied twice a week for four weeks using a GaA1As diode laser at 660 nm, 100 mW power, and 28 J/cm2 energy density.
Number of subjects: 36
Study 31454713 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (NST) oral suspension 100,000 IU used four times daily for 15 days.
Number of subjects: 36
Study 28857709 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbishing (n=85; 67 AM, 18 RC)
Number of subjects: 34
Study 28857709 — intervention group
Group type: COMPARATOR
Intervention: Control (n=89; 59 AM, 30 RC)
Number of subjects: 34
Study 25791325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish + CO2 laser (FV + CO2)
Number of subjects: 14
Study 25791325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 14
Study 25791325 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoride placebo varnish (PV)
Number of subjects: 14
Study 25791325 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoride placebo varnish + CO2 laser (PV + CO2)
Number of subjects: 14
Study 24132190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264
Study 24132190 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264
Study 24132190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (in patients with prior MI)
Number of subjects: 14264
Study 24132190 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (in patients with prior MI)
Number of subjects: 14264
Study 21447050 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 54
Study 21447050 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 54
Study 21447050 — intervention group
Group type: COMPARATOR
Intervention: Sleep diaries
Number of subjects: 54
Study 19359647 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering treatment (Perindopril)
Number of subjects: 6105
Study 17296397 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin-A
Number of subjects: 27
Study 17296397 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 U botulinum toxin-A
Number of subjects: 27
Study 17296397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation-free procedure
Number of subjects: 27
Study 17296397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedure
Number of subjects: 27
Study 15362317 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective headgear
Number of subjects: 301
Study 15362317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguards
Number of subjects: 301
Study 15362317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protective equipment)
Number of subjects: 301
Study 12577435 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingwei Zhitong pill (QWZTP)
Number of subjects: 120
Study 12577435 — intervention group
Group type: COMPARATOR
Intervention: Sifangwei tablet
Number of subjects: 120
Study 9700267 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA (tissue plasminogen activator)
Number of subjects: 0
Study 1416136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20
Study 1416136 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 20
Study 3929374 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 0
Study 3929374 — intervention group
Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 0
Study 30326789 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (∼3 mg/kg)
Number of subjects: 21
Study 30326789 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of caffeine
Number of subjects: 21
Study 30326789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29300752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 44
Study 29300752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27810028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunge ankle dorsiflexion measurement device (LAD)
Number of subjects: 24
Study 27810028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tester A using LAD
Number of subjects: 24
Study 27810028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tester B using LAD
Number of subjects: 24
Study 24152974 — intervention group
Group type: EXPERIMENTAL
Intervention: DelpHi-Intervention conducted by Dementia Care Managers (DCMs) with dementia-specific training; details on dosage and duration not specified.
Number of subjects: 0
Study 24152974 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 22467670 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (pharmacokinetic variability)
Number of subjects: 3382
Study 19216048 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral therapy (ICBT)
Number of subjects: 161
Study 19216048 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐based cognitive‐behavioral therapy (FCBT)
Number of subjects: 161
Study 19216048 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐based education, support and attention (FESA)
Number of subjects: 161
Study 17445222 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class I and II and cytokine gene polymorphisms in healthy elderly individuals
Number of subjects: 0
Study 17445222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine gene polymorphisms in healthy elderly individuals
Number of subjects: 0
Study 17445222 — intervention group
Group type: EXPERIMENTAL
Intervention: Inheritance of extended haplotypes in families with longevity members
Number of subjects: 0
Study 17445222 — intervention group
Group type: COMPARATOR
Intervention: HLA class I and II and cytokine gene polymorphisms in families with longevity members
Number of subjects: 0
Study 14739015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal integration of object information
Number of subjects: 0
Study 14739015 — intervention group
Group type: COMPARATOR
Intervention: Intra-modal integration of object information
Number of subjects: 0
Study 12390820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nifedipine for 2 weeks
Number of subjects: 99
Study 12390820 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 99
Study 9661591 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR polymorphic alleles (b, a, T)
Number of subjects: 42
Study 9661591 — intervention group
Group type: EXPERIMENTAL
Intervention: baT haplotype
Number of subjects: 42
Study 7779153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with Brand 1 of praziquantel
Number of subjects: 0
Study 7779153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with Brand 2 (Distocide) of praziquantel
Number of subjects: 0
Study 7779153 — intervention group
Group type: COMPARATOR
Intervention: Brand 1 of praziquantel alone
Number of subjects: 0
Study 7779153 — intervention group
Group type: COMPARATOR
Intervention: Brand 2 of praziquantel alone
Number of subjects: 0
Study 7779153 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 2 plus cimetidine
Number of subjects: 0
Study 7779153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate or glucose with either Brand 1 or Brand 2
Number of subjects: 0
Study 1972139 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine
Number of subjects: 10
Study 1972139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 429174 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation of the wound with saline and antibiotics
Number of subjects: 162
Study 429174 — intervention group
Group type: COMPARATOR
Intervention: Irrigation of the wound with saline alone
Number of subjects: 162
Study 429174 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigated group
Number of subjects: 162
Study 31880167 — intervention group
Group type: EXPERIMENTAL
Intervention: CFT-based self-help intervention
Number of subjects: 176
Study 31880167 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (usual medical care)
Number of subjects: 176
Study 30972871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr. Wolff Gel (test gel)
Number of subjects: 32
Study 30972871 — intervention group
Group type: COMPARATOR
Intervention: Biotene (control gel)
Number of subjects: 32
Study 27762647 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid peels (10%)
Number of subjects: 0
Study 27762647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (blue LED and red laser lights)
Number of subjects: 0
Study 26143483 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients underwent resting-state fMRI and functional connectivity density mapping (FCD).
Number of subjects: 29
Study 26143483 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis in schizophrenia patients.
Number of subjects: 29
Study 26143483 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls underwent resting-state fMRI and functional connectivity density mapping (FCD).
Number of subjects: 29
Study 23841872 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative seizure control at 12 months after surgery
Number of subjects: 54
Study 23841872 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2A1 as a biomarker
Number of subjects: 54
Study 23841872 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of anti-apoptotic genes
Number of subjects: 54
Study 20653433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash with an antidiscoloration system (ADS)
Number of subjects: 15
Study 20653433 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash (control group)
Number of subjects: 15
Study 19858419 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT on (active therapy)
Number of subjects: 610
Study 19858419 — intervention group
Group type: COMPARATOR
Intervention: CRT off (control)
Number of subjects: 610
Study 17130505 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sucrose diet (25% of total energy intake)
Number of subjects: 13
Study 17130505 — intervention group
Group type: COMPARATOR
Intervention: Low-sucrose diet (10% of total energy intake)
Number of subjects: 13
Study 17130505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study 15448429 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 42
Study 15448429 — intervention group
Group type: COMPARATOR
Intervention: Cow milk challenge during esophageal pH monitoring
Number of subjects: 42
Study 11376649 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg) and Acetaminophen (500 mg) before vaginal misoprostol (800 mcg)
Number of subjects: 200
Study 11376649 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (800 mcg) without prophylactic medication
Number of subjects: 200
Study 11376649 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide and Acetaminophen
Number of subjects: 200
Study 11376649 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol without prophylactic medication
Number of subjects: 200
Study 9151927 — intervention group
Group type: EXPERIMENTAL
Intervention: YNK-01 at 200 mg/d
Number of subjects: 32
Study 9151927 — intervention group
Group type: EXPERIMENTAL
Intervention: YNK-01 at 300 mg/d
Number of subjects: 32
Study 7476236 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with parasite derived antigen (94‐67 KD)
Number of subjects: 25
Study 7476236 — intervention group
Group type: COMPARATOR
Intervention: Antimonial therapy
Number of subjects: 25